CN106890307B - A kind of Chinese medicine composition with effect for reducing blood fat - Google Patents
A kind of Chinese medicine composition with effect for reducing blood fat Download PDFInfo
- Publication number
- CN106890307B CN106890307B CN201710170607.8A CN201710170607A CN106890307B CN 106890307 B CN106890307 B CN 106890307B CN 201710170607 A CN201710170607 A CN 201710170607A CN 106890307 B CN106890307 B CN 106890307B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- chinese medicine
- extract
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of Chinese medicine composition with effect for reducing blood fat, the raw material composition of the Chinese medicine composition is：10 50 parts by weight of Radix Astragali, 5 20 parts by weight of Radix Notoginseng, 5 20 parts by weight of turmeric, 5 20 parts by weight of purple perilla, 5 20 parts by weight of rhizoma zingiberis, 15 parts by weight of red yeast rice.Chinese medicine composition of the present invention has specific lipid-lowering effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine compositions, and in particular to a kind of Chinese medicine composition of effect for reducing blood fat belongs to the traditional Chinese medical science
Medicine field.
Background technology
With the continuous improvement of people's living standards, the incidence of hyperlipidemia is in apparent ascendant trend, hyperlipidemia is again
It is an important factor for inducing coronary heart disease, artery sclerosis, fatty liver, diabetes, obesity etc..Therefore the drop blood of high effect nontoxic is found
Fat drug has important realistic meaning.
Many to the drug research of hyperlipidemia at present, Chinese medicine plays unique advantage in this respect：Medicine source is enriched, poison
Small side effects, curative effect is more definite, and there are many effect for reducing blood fat approach, can flexibly prescription, suit measures to different persons, so with extensively
Wealthy application prospect.Hyperlipidemia is clinically attributed to caused by liver and kidney deficiency, spleen deficiency phlegm wet, qi depression to blood stasis etc. by the traditional Chinese medical science, so treatment
Shi Duoyong tonifies the liver and kidney, invigorating the spleen for eliminating dampness, promoting blood circulation and removing blood stasis, clearing away heat and loosing the bowels, eliminate indigestion and phlegm medicine, and many Chinese medicines have reduction blood fat,
But it emphasizes particularly on different fields in drug effect, the mechanism of action and approach are also different, and the Chinese medicine that number of ways plays comprehensive therapeutic effect is only preferably
Lipid-lowering medicine.
Invention content
The purpose of the present invention is to provide a kind of Chinese medicine compositions with effect for reducing blood fat.
The purpose of the present invention is what is be achieved through the following technical solutions：
A kind of Chinese medicine composition with effect for reducing blood fat, the bulk pharmaceutical chemicals of the Chinese medicine composition include：Radix Astragali, Radix Notoginseng, ginger
Huang, purple perilla, rhizoma zingiberis, red yeast rice.
Preferably, the raw material composition of the Chinese medicine composition is：Radix Astragali 20-50 parts by weight, Radix Notoginseng 5-20 parts by weight, turmeric
5-20 parts by weight, purple perilla 5-20 parts by weight, rhizoma zingiberis 5-20 parts by weight, red yeast rice 1-5 parts by weight.
It is further preferred that the raw material composition of the Chinese medicine composition is：Radix Astragali 22-45 parts by weight, Radix Notoginseng 6-18 weight
Part, turmeric 6-18 parts by weight, purple perilla 6-18 parts by weight, rhizoma zingiberis 6-18 parts by weight, red yeast rice 1.5-4.5 parts by weight.
Still more preferably, the raw material composition of the Chinese medicine composition is：Radix Astragali 25-40 parts by weight, Radix Notoginseng 8-15 weights
Measure part, turmeric 8-15 parts by weight, purple perilla 8-15 parts by weight, rhizoma zingiberis 8-15 parts by weight, red yeast rice 2-4 parts by weight.
Most preferably, the raw material composition of the Chinese medicine composition is：30 parts by weight of Radix Astragali, 10 parts by weight of Radix Notoginseng, turmeric 10
Parts by weight, 10 parts by weight of purple perilla, 10 parts by weight of rhizoma zingiberis, 2 parts by weight of red yeast rice；
Or, the raw material composition of the Chinese medicine composition is：28 parts by weight of Radix Astragali, 12 parts by weight of Radix Notoginseng, 9 parts by weight of turmeric,
12 parts by weight of purple perilla, 9 parts by weight of rhizoma zingiberis, 3 parts by weight of red yeast rice；
Or, the raw material composition of the Chinese medicine composition is：35 parts by weight of Radix Astragali, 9 parts by weight of Radix Notoginseng, 12 parts by weight of turmeric,
9 parts by weight of purple perilla, 12 parts by weight of rhizoma zingiberis, 2 parts by weight of red yeast rice.
The Chinese medicine composition can be by above-mentioned Chinese medicine for raw material composition it is any in the form of, as above-mentioned Chinese medicine mixing after pass through
Crush obtained composition or the mixing of above-mentioned Chinese medicine/routinely extracting method is extracted respectively extract or extract into
One step passes through the active component that polishing purification technique obtains, and can also be the extract/active component further according to routine
The conventional oral dosage formulations that preparation process is prepared；
General extraction methods of the present invention are carried including Soakage extraction, decoction extraction, refluxing extraction, seepage pressure effects, ultrasound
It takes, steam distillation etc.；Extraction solvent includes water, 20~95% ethanol solutions；The polishing purification technique include water extract-alcohol precipitation,
Extraction, silica gel chromatograph post separation, macroreticular resin post separation etc.；The conventional oral dosage formulations include powder, tablet, capsule,
Granula, oral liquid, pill etc..
In traditional Chinese medicinal composition raw materials of the present invention divided by other than bulk pharmaceutical chemicals are fed intake, extract can also be used (effectively
Position) form feed intake, such as Astragalus Root P.E, Notogineng Extract, therefore the present invention further discloses one kind have drop blood
The Chinese medicine composition of fat effect：
A kind of Chinese medicine composition with effect for reducing blood fat, the raw material composition of the Chinese medicine composition are：The Chinese medicine group
The raw material of conjunction object, which forms, is：Astragalus Root P.E 20-50 parts by weight, Notogineng Extract 5-20 parts by weight, Turmeric P.E 5-20 weights
Measure part, extractive of perilla 5-20 parts by weight, Rhizoma Zingiberis extract 5-20 parts by weight, Red Yeast Rice P.E 1-5 parts by weight.
Preferably, the raw material composition of the Chinese medicine composition is：Astragalus Root P.E 22-45 parts by weight, Notogineng Extract 6-
18 parts by weight, Turmeric P.E 6-18 parts by weight, extractive of perilla 6-18 parts by weight, Rhizoma Zingiberis extract 6-18 parts by weight, red yeast rice
Extract 1.5-4.5 parts by weight.
It is further preferred that the raw material composition of the Chinese medicine composition is：Astragalus Root P.E 25-40 parts by weight, Radix Notoginseng carry
Take object 8-15 parts by weight, Turmeric P.E 8-15 parts by weight, extractive of perilla 8-15 parts by weight, Rhizoma Zingiberis extract 8-15 weight
Part, Red Yeast Rice P.E 2-4 parts by weight.
Most preferably, the raw material composition of the Chinese medicine composition is：30 parts by weight of Astragalus Root P.E, 10 weight of Notogineng Extract
Measure part, 10 parts by weight of Turmeric P.E, 10 parts by weight of extractive of perilla, 10 parts by weight of Rhizoma Zingiberis extract, 2 weight of Red Yeast Rice P.E
Part；
Or, the raw material composition of the Chinese medicine composition is：28 parts by weight of Astragalus Root P.E, 12 parts by weight of Notogineng Extract,
9 parts by weight of Turmeric P.E, 12 parts by weight of extractive of perilla, 9 parts by weight of Rhizoma Zingiberis extract, 3 parts by weight of Red Yeast Rice P.E；
Or, the raw material composition of the Chinese medicine composition is：35 parts by weight of Astragalus Root P.E, 9 parts by weight of Notogineng Extract, ginger
Yellow 12 parts by weight of extract, 9 parts by weight of extractive of perilla, 12 parts by weight of Rhizoma Zingiberis extract, 2 parts by weight of Red Yeast Rice P.E.
Each extract is respectively to obtain water after the water extract of each bulk pharmaceutical chemicals or ethanol solution extract or water extract-alcohol precipitation
Extract after extract concentration；Extracting method is this field general extraction methods, such as Soakage extraction, decoction extraction, reflux carry
It takes, seepage pressure effects, ultrasonic extraction, steam distillation etc..
For dosage form of the present invention is enable to realize, pharmaceutically acceptable auxiliary material, example need to be added in when preparing these dosage forms
Such as：Filler, disintegrant, lubricant, suspending agent, adhesive, sweetener, corrigent, preservative, matrix etc..Filler includes：
Starch, pregelatinized starch, lactose, mannitol, chitin, microcrystalline cellulose, sucrose etc.；Disintegrant includes：Starch, pregelatinated form sediment
Powder, microcrystalline cellulose, sodium carboxymethyl starch, crosslinked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linked carboxymethyl fiber
Plain sodium etc.；Lubricant includes：Magnesium stearate, lauryl sodium sulfate, talcum powder, silica etc.；Suspending agent includes：Polyethylene
Pyrrolidones, microcrystalline cellulose, sucrose, agar, hydroxypropyl methyl cellulose etc.；Adhesive includes：Starch slurry, polyvinyl pyrrole
Alkanone, hydroxypropyl methyl cellulose etc.；Sweetener includes：Saccharin sodium, aspartame, sucrose, honey element, enoxolone etc.；It rectifys
Taste agent includes：Sweetener and various essence；Preservative includes：Parabens, benzoic acid, sodium benzoate, sorbic acid and its esters,
Benzalkonium bromide, acetic acid chloroethene are fixed, eucalyptus oil etc.；Matrix includes：PEG6000, PEG4000, insect wax etc..To enable above-mentioned dosage form
It realizes pharmacy of Chinese materia medica, pharmaceutically acceptable other auxiliary material (Fan Biting need to be added in when preparing these dosage forms《Pharmacy of Chinese materia medica》,
The auxiliary material that each dosage form is recorded in Shanghai Science Press December the 1st edition in 1997).
As another aspect of the present invention, the present invention also provides the Chinese medicine compositions to prepare with effect for reducing blood fat
Drug in application.
Each bulk pharmaceutical chemicals of the present invention meet 2015 editions《Chinese Pharmacopoeia》Record.
Radix Astragali invigorating middle warmer and replenishing QI in prescription of the present invention, Gu table Tuoli, plays QI invigorating and is good for the leading work(of fortune, be monarch drug in a prescription；Radix Notoginseng has work
The benefits of blood regulating blood condition, stagnation resolvation are not hindered just, in turmeric can the promoting flow of qi and blood circulation, outside can dispersing wind and cold damp evil, the two compatibility be minister, promoting blood circulation,
Promoting qi circulation and relieving pain；Rhizoma zingiberis invigorating the spleen middle benefit gas, dampness removing lipid-loweringing, purple perilla clearing damp inducing diaphoresis, resolving sputum and stomach, two medicines are adjutant altogether；Make medicine red yeast rice, it can
Reinforcing spleen to promote digestion.Radix Astragali in side enhances body's immunity, can improve the diseases such as treatment deficiency of vital energy weak.Our compatibility is exquisite, with Huang
The drugs such as stilbene, Radix Notoginseng, turmeric, rhizoma zingiberis, purple perilla from phlegm, silt, it is wet, empty start with, quite cut the interpretation of the cause, onset and process of an illness, more than defence month can QI invigorating dampness elimination live.
Chinese medicine composition of the present invention has specific compatibility relationship, and the notable of the prescription can not then be realized by changing compatibility relationship
Effect.
Pharmacological experiments show that prescription of the present invention has specific lipid-lowering effect, and wherein high dose group Bloodlipid-lowering is shown
It writes better than clinical common fat-reducing medicament Effects of Xuezhikang.
Specific embodiment
Embodiment 1
Raw material forms：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g.
Embodiment 2
Raw material forms：Radix Astragali 28g, Radix Notoginseng 12g, turmeric 9g, purple perilla 12g, rhizoma zingiberis 9g, red yeast rice 3g.
Embodiment 3
Raw material forms：Radix Astragali 35g, Radix Notoginseng 9g, turmeric 12g, purple perilla 9g, rhizoma zingiberis 12g, red yeast rice 2g.
Preparation method：Appoint the composition of 1~3 proportioning of Example, add water to cook 2 times, for the first time plus 8 times are measured water,
Decoct 40min, second plus 6 times of amount water, decoct 30min, merging filtrate, concentrate to get.
Embodiment 4
Raw material forms：Radix Astragali 26g, Radix Notoginseng 14g, turmeric 8g, purple perilla 13g, rhizoma zingiberis 9g, red yeast rice 4g.
Embodiment 5
Raw material forms：Radix Astragali 38g, Radix Notoginseng 9g, turmeric 12g, purple perilla 8g, rhizoma zingiberis 14g, red yeast rice 2g.
Embodiment 6
Raw material forms：Radix Astragali 42g, Radix Notoginseng 7g, turmeric 16g, purple perilla 7g, rhizoma zingiberis 18g, red yeast rice 1.5g.
Preparation method：Appoint the composition of 6~9 proportioning of Example, add 70% ethanol solution refluxing extraction 2 times, the
Primary plus 8 times of amount water, extract 1.5h, second plus 6 times of amount water, extract 1h, merging filtrate, concentrate to get.
Embodiment 7
Raw material forms：Radix Astragali 24g, Radix Notoginseng 17g, turmeric 7g, purple perilla 16g, rhizoma zingiberis 6g, red yeast rice 4.5g.
Embodiment 8
Raw material forms：Radix Astragali 22g, Radix Notoginseng 19g, turmeric 5g, purple perilla 20g, rhizoma zingiberis 5g, red yeast rice 4.5g.
Embodiment 9
Raw material forms：Radix Astragali 48g, Radix Notoginseng 6g, turmeric 19g, purple perilla 5g, rhizoma zingiberis 19g, red yeast rice 1g.
Preparation method：Appoint the composition of 7~9 proportioning of Example, add 50% ethanol solution ultrasonic extraction 2 times, the
Primary plus 8 times of amount water, ultrasonic extraction 40min, second plus 6 times of amount water, ultrasonic extraction 30min, merging filtrate, concentrate to get.
Embodiment 10
Raw material forms：Astragalus Root P.E 30g, Notogineng Extract 10g, Turmeric P.E 10g, extractive of perilla 10g, rhizoma zingiberis
Extract 10g, Red Yeast Rice P.E 2g.
Embodiment 11
Raw material forms：Astragalus Root P.E 28g, Notogineng Extract 12g, Turmeric P.E 9g, extractive of perilla 12g, rhizoma zingiberis
Extract 9g, Red Yeast Rice P.E 3g.
Embodiment 12
Raw material forms：Astragalus Root P.E 35g, Notogineng Extract 9g, Turmeric P.E 12g, extractive of perilla 9g, rhizoma zingiberis carry
Take object 12g, Red Yeast Rice P.E 2g.
Each extract described in above example 10-12 is respectively the water extract of each bulk pharmaceutical chemicals.
Embodiment 13
Raw material forms：Astragalus Root P.E 26g, Notogineng Extract 14g, Turmeric P.E 8g, extractive of perilla 13g, rhizoma zingiberis
Extract 9g, Red Yeast Rice P.E 4g.
Embodiment 14
Raw material forms：Astragalus Root P.E 38g, Notogineng Extract 9g, Turmeric P.E 12g, extractive of perilla 8g, rhizoma zingiberis carry
Take object 14g, Red Yeast Rice P.E 2g.
Embodiment 15
Raw material forms：Astragalus Root P.E 42g, Notogineng Extract 7g, Turmeric P.E 16g, extractive of perilla 7g, rhizoma zingiberis carry
Take object 18g, Red Yeast Rice P.E 1.5g.
Each extract described in above example 13-15 is respectively 75% ethanol solution extract of each bulk pharmaceutical chemicals.
Embodiment 16
Raw material forms：Astragalus Root P.E 24g, Notogineng Extract 17g, Turmeric P.E 7g, extractive of perilla 16g, rhizoma zingiberis
Extract 6g, Red Yeast Rice P.E 4.5g.
Embodiment 17
Raw material forms：Astragalus Root P.E 22g, Notogineng Extract 19g, Turmeric P.E 5g, extractive of perilla 20g, rhizoma zingiberis
Extract 5g, Red Yeast Rice P.E 4.5g.
Embodiment 18
Raw material forms：Astragalus Root P.E 48g, Notogineng Extract 6g, Turmeric P.E 19g, extractive of perilla 5g, rhizoma zingiberis carry
Take object 19g, Red Yeast Rice P.E 1g.
Each extract described in above example 16-18 is respectively 50% ethanol solution extract of each bulk pharmaceutical chemicals.
Effect experimental examples
Experimental example 1
1 experiment material
Experimental drug is 1.：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental drug is 2.：Glutinous rehmannia 15g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental drug is 3.：Radix Astragali 30g, lotus leaf 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental drug is 4.：Radix Astragali 30g, Radix Notoginseng 10g, hawthorn 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Preparation method：Take experimental drug 1.-composition of the 4. proportioning, add water to cook 2 times, for the first time plus 8 times of amount water,
Decoct 40min, second plus 6 times of amount water, decoct 30min, merging filtrate, concentrate to get.
2 experimental methods
60 SD rats are divided into 6 groups, respectively blank group, model group, experimental drug 1. -4. group, every group of 10 animals.
In addition to blank control group is fed using normal diet, other each group animals are fed with high lipid food.After 7 days, 3 administration groups are moved
Gavage gives the liquid of corresponding 5 times of Clinical practice dosage to object respectively, and blank control group and model group give the distillation of same volume
Water.After 3 weeks after each group animal chloral hydrate anesthesia, eye socket takes blood, and centrifugation obtains serum, measures T-CHOL (CHO), low-density
Lipoprotein (LDL) is horizontal.
3 experimental results
It the results are shown in Table 1.
1 each group animal lipid of table level (N=10)
| CHO | LDL | |
| Blank group | 1.69±0.34 | 0.45±0.18 |
| Model group | 4.23±0.25△ | 0.89±0.21△ |
| Experimental drug 1. group | 2.54±0.24* | 0.49±0.14* |
| Experimental drug 2. group | 3.67±0.43*○ | 0.67±0.12*○ |
| Experimental drug 3. group | 3.71±0.27*○ | 0.75±0.15*○ |
| Experimental drug 4. group | 3.52±0.34*○ | 0.65±0.24*○ |
Note：Compared with blank group, △ P ＜ 0.05；Compared with model group, * P ＜ 0.05；Compared with experimental drug 1. group, zero
P ＜ 0.05.
The result shows that compared with blank group, model group rats CHO and LDL are significantly increased, and illustrate modeling success.Administration three
Zhou Hou, experimental drug 1. -4. can significantly reduce the CHO and LDL of rat model；And 1. significant effect is better than experiment to experimental drug
Drug 2. -4..
Experimental example 2
1 experiment material
Experimental drug is 1.：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental drug is 2.：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g, cassia seed 10g；
Experimental drug is 3.：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g, prepared RADIX ET RHIZOMA RHEI 10g；
Preparation method：Take experimental drug 1. -3. state the composition of proportioning, add water to cook 2 times, for the first time plus 8 times of amount water, decoct
Boil 40min, second plus 6 times of amount water, decoct 30min, merging filtrate, concentrate to get.
2 experimental methods
50 SD rats are divided into 5 groups, respectively blank group, model group, experimental drug 1. -3. group, every group of 10 animals.
In addition to blank control group is fed using normal diet, other each group animals are fed with high lipid food.After 7 days, 3 administration groups are moved
Gavage gives the liquid of corresponding 5 times of Clinical practice dosage to object respectively, and blank control group and model group give the distillation of same volume
Water.After 3 weeks after each group animal chloral hydrate anesthesia, eye socket takes blood, and centrifugation obtains serum, measures T-CHOL (CHO), low-density
Lipoprotein (LDL) is horizontal.
3 experimental results
It the results are shown in Table 2.
2 each group animal lipid of table level (N=10)
| CHO | LDL | |
| Blank group | 1.46±0.34 | 0.29±0.12 |
| Model group | 4.19±0.48△ | 1.15±0.25△ |
| Experimental drug 1. group | 2.46±0.54* | 0.46±0.13* |
| Experimental drug 2. group | 3.67±0.48*○ | 0.74±0.21*○ |
| Experimental drug 3. group | 3.74±0.61*○ | 0.72±0.19*○ |
Note：Compared with blank group, △ P ＜ 0.05；Compared with model group, * P ＜ 0.05；Compared with experimental drug 1. group, zero
P ＜ 0.05.
The result shows that compared with blank group, model group rats CHO and LDL are significantly increased, and illustrate modeling success.Administration three
Zhou Hou, experimental drug 1. -3. can significantly reduce the CHO and LDL of rat model；And 1. significant effect is better than experiment to experimental drug
Drug 2. -3..
Experimental example 3
1 experiment material
Experimental drug is 1.：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Experimental drug is 2.：Radix Astragali 10g, Radix Notoginseng 5g, turmeric 5g, purple perilla 20g, rhizoma zingiberis 20g, red yeast rice 2g；
Experimental drug is 3.：Radix Astragali 10g, Radix Notoginseng 5g, turmeric 5g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 10g；
Preparation method：Take experimental drug 1. -3. state the composition of proportioning, add water to cook 2 times, for the first time plus 8 times of amount water, decoct
Boil 40min, second plus 6 times of amount water, decoct 30min, merging filtrate, concentrate to get.
2 experimental methods
50 SD rats are divided into 5 groups, respectively blank group, model group, experimental drug 1. -3. group, every group of 10 animals.
In addition to blank control group is fed using normal diet, other each group animals are fed with high lipid food.After 7 days, 3 administration groups are moved
Gavage gives the liquid of corresponding 5 times of Clinical practice dosage to object respectively, and blank control group and model group give the distillation of same volume
Water.After 3 weeks after each group animal chloral hydrate anesthesia, eye socket takes blood, and centrifugation obtains serum, measures T-CHOL (CHO), low-density
Lipoprotein (LDL) is horizontal.
3 experimental results
It the results are shown in Table 3.
3 each group animal lipid of table level (N=10)
| CHO | LDL | |
| Blank group | 2.01±0.24 | 0.41±0.10 |
| Model group | 4.21±0.46△ | 1.12±0.24△ |
| Experimental drug 1. group | 2.51±0.24* | 0.43±0.23* |
| Experimental drug 2. group | 3.64±0.27*○ | 0.82±0.18*○ |
| Experimental drug 3. group | 3.71±0.45*○ | 0.83±0.24*○ |
Note：Compared with blank group, △ P ＜ 0.05；Compared with model group, * P ＜ 0.05；Compared with experimental drug 1. group, zero
P ＜ 0.05.
The result shows that compared with blank group, model group rats CHO and LDL are significantly increased, and illustrate modeling success.Administration three
Zhou Hou, experimental drug 1. -3. can significantly reduce the CHO and LDL of rat model；And 1. significant effect is better than experiment to experimental drug
Drug 2. -3..
Experimental example 4
1 experiment material
Experimental drug：Radix Astragali 30g, Radix Notoginseng 10g, turmeric 10g, purple perilla 10g, rhizoma zingiberis 10g, red yeast rice 2g；
Preparation method：Bulk pharmaceutical chemicals are taken in proportion, are added water to cook 2 times, and for the first time plus 8 times are measured water, decoct 40min, for the second time
Add 6 times amount water, decoct 30min, merging filtrate, concentrate to get.
2 experimental methods
60 SD rats are divided into 6 groups, the respectively high, medium and low dosage group of blank group, model group, experimental drug, positive drug
Effects of Xuezhikang control group, every group of 10 animals.In addition to blank control group is fed using normal diet, other each group animals are with high in fat
Forage feed.After 7 days, gavage gives corresponding liquid to 4 administration group animals respectively, and wherein high dose group gives 5 times of Clinical practices
Dosage, middle dose group give 2.5 times of Clinical practice dosage, low dose group gives 1 times of Clinical practice dosage, positive drug Effects of Xuezhikang to
1 times of Clinical practice dosage, blank control group and model group is given to give the distilled water of same volume.Each group animal is hydrated chlorine after 3 weeks
After aldehyde anesthesia, eye socket takes blood, and centrifugation obtains serum, and it is horizontal to measure T-CHOL (CHO), low-density lipoprotein (LDL).
3 experimental results
It the results are shown in Table 4.
4 each group animal lipid of table level (N=10)
| CHO | LDL | |
| Blank group | 1.97±0.22 | 0.30±0.06 |
| Model group | 4.10±0.70△ | 1.01±0.17△ |
| High dose group | 2.85±0.45* | 0.41±0.12* |
| Middle dose group | 2.91±0.21* | 0.52±0.12* |
| Low dose group | 3.21±0.36* | 0.58±0.19* |
| Positive drug group | 3.22±0.18*○ | 0.57±0.21*○ |
Note：Compared with blank group, △ P ＜ 0.05；Compared with model group, * P ＜ 0.05；Compared with high dose group, zero P ＜
0.05
The result shows that present invention determine that prescription there is specific lipid-lowering effect, in, low dose group curative effect and positive drug blood
Fat health is suitable, and high dose group Bloodlipid-lowering is significantly better than clinical common fat-reducing medicament Effects of Xuezhikang.
Claims (9)
1. a kind of Chinese medicine composition with effect for reducing blood fat, which is characterized in that the raw material of the Chinese medicine composition, which forms, is：It is yellow
It is stilbene 20-50 parts by weight, Radix Notoginseng 5-20 parts by weight, turmeric 5-20 parts by weight, purple perilla 5-20 parts by weight, rhizoma zingiberis 5-20 parts by weight, red
Bent 1-5 parts by weight.
2. Chinese medicine composition as described in claim 1, which is characterized in that the raw material of the Chinese medicine composition, which forms, is：Radix Astragali
22-45 parts by weight, Radix Notoginseng 6-18 parts by weight, turmeric 6-18 parts by weight, purple perilla 6-18 parts by weight, rhizoma zingiberis 6-18 parts by weight, red yeast rice
1.5-4.5 parts by weight；
Or, Radix Astragali 25-40 parts by weight, Radix Notoginseng 8-15 parts by weight, turmeric 8-15 parts by weight, purple perilla 8-15 parts by weight, rhizoma zingiberis 8-15
Parts by weight, red yeast rice 2-4 parts by weight.
3. Chinese medicine composition as claimed in claim 2, which is characterized in that the raw material of the Chinese medicine composition, which forms, is：Radix Astragali
30 parts by weight, 10 parts by weight of Radix Notoginseng, 10 parts by weight of turmeric, 10 parts by weight of purple perilla, 10 parts by weight of rhizoma zingiberis, 2 parts by weight of red yeast rice；
Or, the raw material composition of the Chinese medicine composition is：28 parts by weight of Radix Astragali, 12 parts by weight of Radix Notoginseng, 9 parts by weight of turmeric, purple perilla
12 parts by weight, 9 parts by weight of rhizoma zingiberis, 3 parts by weight of red yeast rice；
Or, the raw material composition of the Chinese medicine composition is：35 parts by weight of Radix Astragali, 9 parts by weight of Radix Notoginseng, 12 parts by weight of turmeric, purple perilla 9
Parts by weight, 12 parts by weight of rhizoma zingiberis, 2 parts by weight of red yeast rice.
4. such as claim 1-3 any one of them Chinese medicine compositions, which is characterized in that each bulk pharmaceutical chemicals warp of Chinese medicine composition
Crush the extract for obtained composition or the mixing of each bulk pharmaceutical chemicals/routinely extracting method is extracted respectively or extract warp
It crosses active component that polishing purification technique obtains or the extract/active component is prepared according to conventional formulation technique
Preparation.
5. Chinese medicine composition as claimed in claim 4, which is characterized in that the general extraction methods include Soakage extraction, decoct
Boil any one in extraction, refluxing extraction, seepage pressure effects, ultrasonic extraction, steam distillation；Extraction solvent include water or 20~
95% ethanol solution；The polishing purification technique includes water extract-alcohol precipitation, extraction, silica gel chromatograph post separation and macroporous resin column point
From；The preparation includes powder, tablet, capsule, granule, oral liquid or pill.
6. a kind of Chinese medicine composition with effect for reducing blood fat, which is characterized in that the raw material of the Chinese medicine composition, which forms, is：It is yellow
Stilbene extract 20-50 parts by weight, Notogineng Extract 5-20 parts by weight, Turmeric P.E 5-20 parts by weight, extractive of perilla 5-20
Parts by weight, Rhizoma Zingiberis extract 5-20 parts by weight, Red Yeast Rice P.E 1-5 parts by weight.
7. Chinese medicine composition as claimed in claim 6, which is characterized in that the raw material of the Chinese medicine composition, which forms, is：Radix Astragali
Extract 22-45 parts by weight, Notogineng Extract 6-18 parts by weight, Turmeric P.E 6-18 parts by weight, extractive of perilla 6-18 weights
Measure part, Rhizoma Zingiberis extract 6-18 parts by weight, Red Yeast Rice P.E 1.5-4.5 parts by weight；
Or, the raw material composition of the Chinese medicine composition is：Astragalus Root P.E 25-40 parts by weight, Notogineng Extract 8-15 parts by weight,
Turmeric P.E 8-15 parts by weight, extractive of perilla 8-15 parts by weight, Rhizoma Zingiberis extract 8-15 parts by weight, Red Yeast Rice P.E 2-4
Parts by weight.
8. Chinese medicine composition as claimed in claim 7, which is characterized in that the raw material of the Chinese medicine composition, which forms, is：Radix Astragali
30 parts by weight of extract, 10 parts by weight of Notogineng Extract, 10 parts by weight of Turmeric P.E, 10 parts by weight of extractive of perilla, rhizoma zingiberis
10 parts by weight of extract, 2 parts by weight of Red Yeast Rice P.E；
Or, the raw material composition of the Chinese medicine composition is：28 parts by weight of Astragalus Root P.E, 12 parts by weight of Notogineng Extract, turmeric
9 parts by weight of extract, 12 parts by weight of extractive of perilla, 9 parts by weight of Rhizoma Zingiberis extract, 3 parts by weight of Red Yeast Rice P.E；
Or, the raw material composition of the Chinese medicine composition is：35 parts by weight of Astragalus Root P.E, 9 parts by weight of Notogineng Extract, turmeric carry
Take 12 parts by weight of object, 9 parts by weight of extractive of perilla, 12 parts by weight of Rhizoma Zingiberis extract, 2 parts by weight of Red Yeast Rice P.E.
9. such as application of claim 1-3, the 6-8 any one of them Chinese medicine composition in blood lipid-lowering medicine is prepared.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710170607.8A CN106890307B (en) | 2017-03-21 | 2017-03-21 | A kind of Chinese medicine composition with effect for reducing blood fat |
| PCT/CN2018/079652 WO2018171585A1 (en) | 2017-03-21 | 2018-03-20 | Chinese medicine composition for lowering blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710170607.8A CN106890307B (en) | 2017-03-21 | 2017-03-21 | A kind of Chinese medicine composition with effect for reducing blood fat |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106890307A CN106890307A (en) | 2017-06-27 |
| CN106890307B true CN106890307B (en) | 2018-07-10 |
Family
ID=59192986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710170607.8A Active CN106890307B (en) | 2017-03-21 | 2017-03-21 | A kind of Chinese medicine composition with effect for reducing blood fat |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106890307B (en) |
| WO (1) | WO2018171585A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101297949A (en) * | 2008-05-15 | 2008-11-05 | 天科仁祥技术（北京）有限责任公司 | Chinese medicine for preventing and treating hyperlipemia and preparation thereof |
| CN103372175A (en) * | 2012-04-27 | 2013-10-30 | 北京北大维信生物科技有限公司 | Pharmaceutical composition as well as preparation method and application thereof |
| CN105362936A (en) * | 2015-11-25 | 2016-03-02 | 天津天狮生物发展有限公司 | Composition capable of assisting blood lipid reducing and preparation method of composition |
| CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
| CN106309551A (en) * | 2015-07-03 | 2017-01-11 | 华北制药秦皇岛有限公司 | Perilla seed compound preparation and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486730A (en) * | 2003-07-24 | 2004-04-07 | 上海绿谷（集团）有限公司 | Capsule prepn for regulating blood fat and blood pressure |
| CN105433260A (en) * | 2015-11-12 | 2016-03-30 | 北京至御科技有限公司 | Health-care food for reducing blood fat and preparation process thereof |
-
2017
- 2017-03-21 CN CN201710170607.8A patent/CN106890307B/en active Active
-
2018
- 2018-03-20 WO PCT/CN2018/079652 patent/WO2018171585A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101297949A (en) * | 2008-05-15 | 2008-11-05 | 天科仁祥技术（北京）有限责任公司 | Chinese medicine for preventing and treating hyperlipemia and preparation thereof |
| CN103372175A (en) * | 2012-04-27 | 2013-10-30 | 北京北大维信生物科技有限公司 | Pharmaceutical composition as well as preparation method and application thereof |
| CN106309551A (en) * | 2015-07-03 | 2017-01-11 | 华北制药秦皇岛有限公司 | Perilla seed compound preparation and preparation method thereof |
| CN105362936A (en) * | 2015-11-25 | 2016-03-02 | 天津天狮生物发展有限公司 | Composition capable of assisting blood lipid reducing and preparation method of composition |
| CN105641509A (en) * | 2016-01-14 | 2016-06-08 | 吕海峰 | Traditional Chinese medicine composition for preventing and treating cardiovascular and cerebrovascular disease and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106890307A (en) | 2017-06-27 |
| WO2018171585A1 (en) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1814215A (en) | Medicine for treating gout and gout arthritis | |
| CN104436145B (en) | It is a kind of to prevent and/or treatment allergic rhinitis and the pharmaceutical composition of allergic asthma | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN106890307B (en) | A kind of Chinese medicine composition with effect for reducing blood fat | |
| CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN104095940B (en) | A kind of Chinese medicine composition for the treatment of gout | |
| CN113058024A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN102940850B (en) | Medicine composition for treating gout | |
| CN106075229A (en) | A kind of Chinese medicinal composition preparation treating anemopyretic cold | |
| CN108143875B (en) | Traditional Chinese medicine composition for treating diabetic gastroparesis and preparation method thereof | |
| CN102526509B (en) | Medicine for treating hepatomegaly | |
| CN107970310B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN100355447C (en) | Compound preparation for treating liver fibrosis and its preparing method | |
| CN112755137B (en) | Traditional Chinese medicine composition for treating mild and moderate knee osteoarthritis and application thereof | |
| CN1814217A (en) | Chinese medicine composition for treating rheumatoid arthritis and use thereof | |
| CN114903939B (en) | New medical application of Jingfeng preparation | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity | |
| CN110215474B (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN103223143B (en) | Traditional Chinese medicine composition for treating simple obesity, and preparation method and application thereof | |
| CN102133274A (en) | Chinese medicinal composition | |
| CN107865932A (en) | A kind of Chinese medicine composition with effect of weight reducing | |
| CN1899416A (en) | Chinese medicine composition for treating rheumatism and its use | |
| CN1063074C (en) | Chinese herbs injection for treating oncoma (cancer) and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |